参考文献/References:
[1] Kusumoto FM,Schoenfeld MH,Barrett C,et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,and the Heart Rhythm Society [J]. J Am Coll Cardiol,2019,74(7):932-987.
[2] Wung SF. Bradyarrhythmias:clinical presentation,diagnosis,and management[J]. Crit Care Nurs Clin North Am,2016,28(3):297-308.
[3] Baruteau AE,Probst V,Abriel H. Inherited progressive cardiac conduction disorders[J]. Curr Opin Cardiol,2015,30(1):33-39.
[4] Cheng L,Li X,Zhao L,et al. Reevaluating the mutation classification in genetic studies of bradycardia using ACMG/AMP variant classification framework[J]. Int J Genomics,2020,2020:2415850.
[5] Asatryan B,Medeiros-Domingo A. Molecular and genetic insights into progressive cardiac conduction disease[J]. Europace,2019,21(8):1145-1158.
[6] Wallace MJ,El Refaey M,Mesirca P,et al. Genetic complexity of sinoatrial node dysfunction[J]. Front Genet,2021,12:654925.
[7] van Campenhout MJH,Yaksh A,Kik C,et al. Bachmann’s bundle:a key player in the development of atrial fibrillation?[J]. Circ Arrhythm Electrophysiol,2013,6(5):1041-1046.
[8] Difrancesco D. The role of the funny current in pacemaker activity[J]. Circ Res,2010,106(3):434-446.
[9] Verkerk AO,Wilders R. Pacemaker activity of the human sinoatrial node:effects of HCN4 mutations on the hyperpolarization-activated current[J]. Europace,2014,16(3):384-395.
[10] Yang B,Huang Y,Zhang H,et al. Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome[J]. J Mol Cell Cardiol,2020,138:291-303.
[11] Yanni J,D’souza A,Wang Y,et al. Silencing miR-370-3p rescues funny current and sinus node function in heart failure[J]. Sci Rep,2020,10(1):11279.
[12] Yang Y,Liu Y,Dong X,et al. Human KCNQ1 S140G mutation is associated with atrioventricular blocks[J]. Heart Rhythm,2007,4(5):611-618.
[13] Rinné S,Ortiz-Bonnin B,Stallmeyer B,et al. POPDC2 a novel susceptibility gene for conduction disorders[J]. J Mol Cell Cardiol,2020,145:74-83.
[14] Mangoni ME,Traboulsie A,Leoni AL,et al. Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/alpha1G T-type calcium channels[J]. Circ Res,2006,98(11):1422-1430.
[15] Rezazadeh S,Duff HJ. Genetic determinants of hereditary bradyarrhythmias:a contemporary review of a diverse group of disorders[J]. Can J Cardiol,2017,33(6):758-767.
[16] Yang X,Mao X,Xu G,et al. Estradiol up-regulates L-type Ca2+ channels via membrane-bound estrogen receptor/phosphoinositide-3-kinase/Akt/cAMP response element-binding protein signaling pathway[J]. Heart Rhythm,2018,15(5):741-749.
[17] Schott JJ,Alshinawi C,Kyndt F,et al. Cardiac conduction defects associate with mutations in SCN5A[J]. Nat Genet,1999,23(1):20-21.
[18] Wang Q,Shen J,Splawski I,et al. SCN5A mutations associated with an inherited cardiac arrhythmia,long QT syndrome[J]. Cell,1995,80(5):805-811.
[19] Mcnair WP,Sinagra G,Taylor MR,et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism[J]. J Am Coll Cardiol,2011,57(21):2160-2168.
[20] Hong KW,Lim JE,Kim JW,et al. Identification of three novel genetic variations associated with electrocardiographic traits(QRS duration and PR interval) in East Asians[J]. Hum Mol Genet,2014,23(24):6659-6667.
[21] Gusev K,Khudiakov A,Zaytseva A,et al. Impact of the DSP-H1684R genetic variant on ion channels activity in iPSC-derived cardiomyocytes[J]. Cell Physiol Biochem,2020,54(4):696706.
[22] Saito Y,Nakamura K,Nishi N,et al. TRPM4 mutation in patients with ventricular noncompaction and cardiac conduction disease[J]. Circ Genom Precis Med,2018,11(5):e002103.
[23] Leybaert L,Lampe PD,Dhein S,et al. Connexins in cardiovascular and neurovascular health and disease:pharmacological implications[J]. Pharmacol Rev,2017,69(4):396-478.
[24] Makita N,Seki A,Sumitomo N,et al. A connexin40 mutation associated with a malignant variant of progressive familial heart block typeⅠ[J]. Circ Arrhythm Electrophysiol,2012,5(1):163-172.
[25] Qiu Y,Zheng J,Chen S,et al. Connexin mutations and hereditary diseases[J]. Int J Mol Sci,2022,23(8):4255.
[26] Koenig SN,Mohler PJ. The evolving role of ankyrin-B in cardiovascular disease[J]. Heart Rhythm,2017,14(12):1884-1889.
[27] Mohler PJ,Schott JJ,Gramolini AO,et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death[J]. Nature,2003,421(6923):634-639.
[28] Gazzerro E,Sotgia F,Bruno C,et al. Caveolinopathies:from the biology of caveolin-3 to human diseases[J]. Eur J Hum Genet,2010,18(2):137-145.
[29] Holm H,Gudbjartsson DF,Sulem P,et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome[J]. Nat Genet,2011,43(4):316-320.
[30] Wolf CM,Arad M,Ahmad F,et al. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations[J]. Circulation,2008,117(2):144-154.
[31] Patel V,Asatryan B,Siripanthong B,et al. State of the art review on genetics and precision medicine in arrhythmogenic cardiomyopathy[J]. Int J Mol Sci,2020,21(18):6615.
[32] Varela D,Varela T,Conceicao N,et al. Functional analysis of two novel TBX5 variants present in individuals with Holt-Oram syndrome with different clinical manifestations[J]. Mol Genet Genomics,2021,296(4):809-821.
[33] Hu YF,Dawkins JF,Cho HC,et al. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block[J]. Sci Transl Med,2014,6(245):245ra94.
[34] Choudhury M,Black N,Alghamdi A,et al. TBX18 overexpression enhances pacemaker function in a rat subsidiary atrial pacemaker model of sick sinus syndrome[J]. J Physiol,2018,596(24):6141-6155.
[35] Dubik N,Mai S. Lamin A/C:function in normal and tumor cells[J]. Cancers(Basel),2020,12(12) :3688.
[36] Pagon RA,Adam MP,Ardinger HH,et al. LMNA-related dilated cardiomyopathy—GeneReviews(?)[J]. University of Washington,Seattle:1993.
[37] Lai ZF,Chen YZ. Evidence,hypotheses and significance of MAP kinase TNNI3K interacting with its partners[J]. World J Hypertens,2012,2(2):7.
[38] Lodder EM,Scicluna BP,Milano A,et al. Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction[J]. PLoS Genet,2012,8(12):e1003113.
[39] Musunuru K,Hershberger RE,Day SM,et al. Genetic testing for inherited cardiovascular diseases:a scientific statement from the American Heart Association[J]. Circ Genom Precis Med,2020,13(4):e000067.
[40] Wilde AAM,Semsarian C,Marquez MF,et al. European Heart Rhythm Association(EHRA)/Heart Rhythm Society(HRS)/Asia Pacific Heart Rhythm Society(APHRS)/Latin American Heart Rhythm Society(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases[J]. Europace,2022,24(8):1307-1367.